Phase 3 trial with dispersible arterolane maleate and piperaquine tablets in pediatric malaria patients
- Conditions
- Health Condition 1: null- Acute uncomplicated P.vivax malaria in pediatric patients
- Registration Number
- CTRI/2015/08/006087
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Patients must fulfil the following inclusion criteria to be eligible for enrolment into the study:
1.Children of either sex (male or female) aged between 6 months to 12 years (both inclusive).
2.Parent/Guardian/LAR willing to undergo audio visual recording of the consent process and provide a written informed consent by parent/guardian/LAR. If parent/guardian/LAR is unable to provide informed consent in writing, a thumbprint on informed consent document to indicate consent in the presence of at least one witness is acceptable.
3.Minimum body weight of 5 kg.
4.Presence of acute symptomatic uncomplicated malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. vivax parasites >=250/ µL of blood.
5.Absence of acute severe malnutrition (defined as weight-for-height below -3 standard deviation of WHO normalized reference values and mid-upper arm circumference <115 mm)
6.Able to take drugs under study by the oral route
7.Minimum Haemoglobin (Hb) level of >8 gm/dL.
8.Presence of fever (axillary temperature >=37.5 °C or oral >=38 °C) or a history of fever in the past 24 hours.
9.Willingness and ability to comply with the study protocol for the duration of the study.
If any of the following conditions apply, the patient should not be enrolled in the study.
1.Known allergy to arterolane maleate, artesunate, artemisinin derived products, piperaquine, chloroquine, primaquine, excipients of these drugs or any other related drugs.
2.Patients with severe malaria as per WHO criteria.
3.Presence of general danger signs of severe malaria among children 5 years old (as per WHO)
4.Mixed infection with another Plasmodium species at the time of presentation (including P. falciparum, P. ovale and P. malariae).
5.Infants with a history of hyperbilirubinemia during the neonatal period.
6.Patients with history of hemolytic anaemia or methemoglobinemia.
7.Use of concomitant medications that may induce haemolysis or haemolytic anaemia or depressants of myeloid element of the bone marrow.
8.Any antimalarial treatment during 1 month prior to screening, as assessed by medical history.
9.Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhea defined as 3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening).
10.Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole, doxycycline & malarone.
11.Patients with significant disease(s), disorder(s) other than malaria that in the opinion of the Investigator may (i) put the patient at risk because of participation in the study or (ii) interfere with the study evaluations or (iii) cause concern regarding patientsâ?? ability to participate in the study.
12.Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management, including QTc interval 450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block.
13.Patients with known significant renal or hepatic impairment or electrolyte imbalance indicated by any of the following laboratory evaluations at screening:
•Serum creatinine 1.5 Ã? upper limit of normal (ULN)
•Aspartate transaminase 2.5 Ã? ULN
•Alanine transaminase 2.5 Ã? ULN
•Serum bilirubin 3 mg/dL
•Serum potassium Lower limit of Normal (LLN)
•Serum Sodium LLN
14.Patients who have had a splenectomy as confirmed by history or clinical examination.
15.Patients who are G6PD deficient indicated by laboratory investigation at screening.
16.Patients with history of any retinal/ visual field defects or auditory defects of any etiology assessed on the basis of history.
17.Patients with psoriasis and porphyria assessed on the basis of history.
18.Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine, etc)
19.Participation in any investigational drug study at least 3 months prior to screening.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method